Head-to-head · WeighScore
Good Girl Rx vs Zealthy
The verdict
Good Girl Rx takes it — 63.9/100 to 46.7/100.
Good Girl Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Good Girl Rx (Good Girl LLC) offers compounded semaglutide and tirzepatide in injectable, microdose, and oral dissolving tablet (ODT) formats.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Good Girl Rx | Zealthy |
|---|---|---|
| WeighScore | 63.9/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #251 | #496 |
| Semaglutide | $134/mo (starting dose, annual plan, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $235/mo (starting dose, compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #251 · C
Strengths
- LegitScript certified
- Multiple formats — injectable, microdose, and ODT pills — for both semaglutide and tirzepatide
- Dispensed by licensed 503A or 503B pharmacies
- Limited brand-name options available (Ozempic, Wegovy, Zepbound, Mounjaro)
- Named legal entity with a Nashville address
Where it loses points
- State availability not disclosed
- Very new brand — founded January 2025
- Celebrity-founded (Savannah Chrisley) — brand vs clinical credibility
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.